Mohajer, Bahram
Moradi, Kamyar
Guermazi, Ali
Dolatshahi, Mahsa
Zikria, Bashir
Najafzadeh, Nima
Kalyani, Rita R.
Roemer, Frank W.
Berenbaum, Francis
Demehri, Shadpour http://orcid.org/0000-0001-6398-8448
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR079620-01)
Article History
Received: 8 April 2022
Revised: 1 July 2022
Accepted: 24 July 2022
First Online: 11 August 2022
Declarations
:
: Dr. Shadpour Demehri takes full responsibility for the work as a whole, including the study design, access to data, and the decision to submit and publish the manuscript.
: FWR is chief marketing officer and shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Calibr – California Institute of Biomedical Research and Grünenthal GmbH. AG is a shareholder of BICL and consultant to Pfizer, TissueGene, MerckSerono, Novartis, Regeneron, and AstraZeneca. FB reports personal fees from AstraZeneca, Boehringer, Bone Therapeutics, CellProthera, Expanscience, Galapagos, Gilead, Grunenthal, GSK, Eli Lilly, Merck Sereno, MSD, Nordic, Nordic Bioscience, Novartis, Pfizer, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, 4P Pharma, grants from TRB Chemedica, non-financial support from 4Moving Biotech, outside the submitted work. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: Subjects have given informed consent before participating in the Osteoarthritis Initiative (OAI) project.
: The medical ethics review boards of the University of California, San Francisco (Approval Number: 10-00532) and the four clinical centers of osteoarthritis initiative project recognized the project as Health Insurance Portability and Accountability Act (HIPAA)–compliant.
: • Retrospective• Observational• Multi-center study